Literature DB >> 21245972

6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

.   

Abstract

Entities:  

Year:  2009        PMID： 21245972      PMCID： PMC2997296     

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN： 1660-3796            Impact factor:   3.747


× No keyword cloud information.
  54 in total

1.  Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

Authors:  A Villar; S Aronis; M Morfini; E Santagostino; G Auerswald; H F Thomsen; E Erhardtsen; P L F Giangrande
Journal:  Haemophilia       Date:  2004-07       Impact factor: 4.287

2.  Haemophilia care within the United Kingdom.

Authors:  C A Ludlam
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

3.  A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII.

Authors:  H Ekert; D A Price; J L Lane; F L Dean
Journal:  Aust N Z J Med       Date:  1979-06

4.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Authors:  Pier M Mannucci; Juan Chediak; Wahid Hanna; John Byrnes; Marlies Ledford; Bruce M Ewenstein; Anastassios D Retzios; Barbara A Kapelan; Richard S Schwartz; Craig Kessler
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

Review 5.  Genetic risk factors for inhibitors to factors VIII and IX.

Authors:  J Oldenburg; A Pavlova
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

Review 6.  Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.

Authors:  A Gringeri; P M Mannucci
Journal:  Haemophilia       Date:  2005-11       Impact factor: 4.287

7.  On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.

Authors:  K Steen Carlsson; S Höjgård; A Glomstein; S Lethagen; S Schulman; L Tengborn; A Lindgren; E Berntorp; B Lindgren
Journal:  Haemophilia       Date:  2003-09       Impact factor: 4.287

8.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

Authors:  J Addiego; C Kasper; C Abildgaard; M Hilgartner; J Lusher; B Glader; L Aledort
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

9.  A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.

Authors:  K Peerlinck; J Arnout; J G Gilles; J M Saint-Remy; J Vermylen
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

10.  A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.

Authors:  L M Aledort; R H Haschmeyer; H Pettersson
Journal:  J Intern Med       Date:  1994-10       Impact factor: 8.989
View more
  1 in total

1.  Peptide valency plays an important role in the activity of a synthetic fibrin-crosslinking polymer.

Authors:  Robert J Lamm; Esther B Lim; Katie M Weigandt; Lilo D Pozzo; Nathan J White; Suzie H Pun
Journal:  Biomaterials       Date:  2017-04-05       Impact factor: 12.479
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.